COMPOSITIONS OF OBETICHOLIC ACID AND METHODS OF USE
The disclosure relates to obeticholic acid formulations with improved stability, dissolution, and/or solubility, methods of preparing the same for use and methods of treating various diseases and conditions.
1 . A method of treating liver fibrosis in a subject in need thereof, said method comprising administering to the subject a tablet comprising an intra-granular portion and an extra-granular portion, the intra-granular portion comprising obeticholic acid or a pharmaceutically acceptable salt or amino acid conjugate thereof in an amount of about 1 to about 50 mg, and one or more pharmaceutically acceptable excipients, and the extra-granular portion comprising one or more pharmaceutically acceptable excipients,
wherein at least one pharmaceutically acceptable excipient in the tablet has an alcohol content of less than about 6% (w/w),
wherein the amount is a starting dose, an adjusted dose or a re-adjusted dose; and
wherein the tablet is administered daily (QD), every other day (Q2D), once a week (QW), twice a week (BID), three times a week (TIW), once a month (QM), or twice a month (Q2M).
2 . The method of claim 1 , wherein the amount is about 1 mg to about 25 mg.
3 . The method of claim 1 , wherein the tablet comprises obeticholic acid.
4 . The method of claim 1 wherein the amount is a starting dose, and the tablet is administered in a titration period.
5 . The method of claim 4 , wherein the titration period is from 1 to 6 months.
6 . The method of claim 5 , wherein the titration period is 3 months or 6 months.
7 . The method of claim 1 , wherein the amount is 25 mg, and the tablet is administered daily.
8 . The method of claim 1 , wherein the amount is 10 mg, and the tablet is administered daily.
9 . The method of claim 1 , wherein the amount is about 1 mg to about 5 mg, and the tablet is administered daily.
10 . A method of treating liver fibrosis in a subject in need thereof, said method comprising administering to the subject a tablet comprising an intra-granular portion and an extra-granular portion, the intra-granular portion comprising obeticholic acid or a pharmaceutically acceptable salt or amino acid conjugate thereof in an amount of about 1 to about 50 mg, and one or more pharmaceutically acceptable excipients, and the extra-granular portion comprising one or more pharmaceutically acceptable excipients,
wherein the obeticholic acid or the pharmaceutically acceptable salt or amino acid conjugate thereof is in the form of jet-milled particles, and wherein at least 50% of the particles have a diameter of 200 μm or less;
wherein at least one pharmaceutically acceptable excipient in the tablet has an alcohol content of less than about 6% (w/w);
wherein the amount is a starting dose, an adjusted dose or a re-adjusted dose; and
wherein the tablet is administered daily (QD), every other day (Q2D), once a week (QW), twice a week (BID), three times a week (TIW), once a month (QM), or twice a month (Q2M).
11 . The method of claim 10 , wherein the amount is about 1 mg to about 25 mg.
12 . The method of claim 10 , wherein the tablet comprises obeticholic acid.
13 . The method of claim 10 wherein the amount is a starting dose, and the tablet is administered in a titration period.
14 . The method of claim 13 , wherein the titration period is from 1 to 6 months.
15 . The method of claim 14 , wherein the titration period is 3 months or 6 months.
16 . The method of claim 10 , wherein the amount is 25 mg, and the tablet is administered daily.
17 . The method of claim 10 , wherein the amount is 10 mg, and the tablet is administered daily.
18 . The method of claim 10 , wherein the amount is about 1 mg to about 5 mg, and the tablet is administered daily.